"Telehealth company Hims & Hers dropped its plan to offer a knockoff version of the weight-loss pill Wegovy on Saturday - two days after it announced the new drug and one day after the Food and Drug Administration threatened to restrict access to the ingredients needed to copy popular weight-loss medications. Hims had said Thursday that it would offer a compounded version of the new Wegovy pill that drugmaker Novo Nordisk just began selling last month."
"Hims' own website still touted the new semaglutide pill offering Saturday afternoon - hours after it announced on X that it will no longer sell the medicine. Semaglutide is the chemical name for Wegovy."Since launching the compounded semaglutide pill on our platform, we've had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment," Hims said in its statement."
Hims & Hers announced, then quickly abandoned, plans to sell a compounded semaglutide pill modeled on Novo Nordisk's Wegovy. Novo Nordisk threatened to sue, and the FDA said it would limit access to active ingredients used in GLP-1 weight-loss drugs, prompting Hims to stop the offering. The company's website briefly continued to list the pill after the announcement. Hims said constructive conversations with industry stakeholders led to the decision and reiterated commitment to safe, affordable care. Hims did not specify whether it will change the compounded injectable weight-loss products it already sells. The planned price undercut Novo's monthly fee.
Read at Fast Company
Unable to calculate read time
Collection
[
|
...
]